Bruker develops mass spectrometry solutions in collaboration with pharmaceutical customers with the goal of helping scientists get confident results to advance their drug discovery projects.

Recent innovations have brought transformative capabilities that help accelerate the drug development cycle.

• Trapped ion mobility spectrometry (TIMS) dramatically improves speed and sensitivity for protein digests with PASEF. These benefits can translate to better statistics for biomarker discovery, answer immunogenicity related question by analyzing MHC-bound peptides or identify host cell proteins (HCPs).
• Leading ultrahigh resolution QTOFs support bioanalytical and CMC projects, by delivering unmatched intact protein data with sub-ppm mass accuracy.
• Collisional cross section (CCS) aware workflows use the selectivity of ion mobility to separate isomers. This enhances data for many applications from API characterization, to metabolite ID and peptide mapping.
• The MALDI Pharma Pulse makes screening 100,000's of compounds per week possible. This label-free assay benefits from the specificity of MS and affords unique insights when searching for enzymatic activity or screening synthetic chemistry libraries.
• Mass spectrometry imaging and spatialOMx reveals the localization of drugs, metabolites or biomarkers directly on tissue. This circumvents the need for homogenizing tissue (the "well-stirred model") and delivers richer information about potential toxicity or mechanism of action.

Join us on the chat or in a 1:1 meeting to discuss how these technologies can reduce risk and accelerate projects.